Pharmacological Treatment of Perianal Gland Tumors in Male Dogs.
antihormonal therapy
male dogs
perianal gland tumors
treatment
Journal
Animals : an open access journal from MDPI
ISSN: 2076-2615
Titre abrégé: Animals (Basel)
Pays: Switzerland
ID NLM: 101635614
Informations de publication
Date de publication:
28 Jan 2023
28 Jan 2023
Historique:
received:
13
12
2022
revised:
20
01
2023
accepted:
25
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
The presence of androgen (AR) and estrogen (ER) receptors has been demonstrated both in normal perianal (hepatoid) glands and in perianal tumors. The aim of this study was to demonstrate the relationship between the expression of AR and ER in perianal gland tumors and the effectiveness of antihormonal treatment. The study was performed on 41 male dogs with neoplastic lesions of the anal region. Histopathological evaluation of the lesions revealed 24 adenomas, 12 epitheliomas, and five carcinomas. Treatment was administered orally with tamoxifen at a dose of 1 mg/kg BW and cyproterone acetate at a dose of 5 mg/kg. Tumor diameters were measured regularly with calipers and recorded in millimeters starting with the measurement before treatment, and then after 1, 2, 3, 6, 12, 18, and 24 months of therapy. The results show that hepatoid adenomas that are characterized by high expression of AR and ER receptors respond positively to antihormonal therapy, resulting in complete tumor regression. For locally malignant hepatoid epitheliomas and carcinomas with low expression of AR and ER receptors, antihormonal therapy makes it possible to reduce the size of the tumor, but does not make it possible to cure it completely.
Identifiants
pubmed: 36766353
pii: ani13030463
doi: 10.3390/ani13030463
pmc: PMC9913509
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : The Polish Ministry of Education and Science
ID : No NN308295937
Références
In Vivo. 2019 May-Jun;33(3):731-735
pubmed: 31028190
Vet Pathol. 2021 Mar;58(2):325-331
pubmed: 33208018
Endocr Relat Cancer. 2021 Jan;28(1):27-37
pubmed: 33112838
Acta Vet Scand. 2010 Dec 22;52:67
pubmed: 21176231
Asian Pac J Trop Biomed. 2013 Jul;3(7):580-3
pubmed: 23835432
Animals (Basel). 2021 Mar 19;11(3):
pubmed: 33808541
J Urol. 1969 Jan;101(1):81-5
pubmed: 4178189
Am J Cancer Res. 2017 Aug 01;7(8):1617-1636
pubmed: 28861319
Res Vet Sci. 2006 Oct;81(2):231-6
pubmed: 16427103
In Vivo. 2014 Sep-Oct;28(5):871-7
pubmed: 25189902
Sign Transduct Insights. 2016 Feb 10;5:1-7
pubmed: 26989346
Urol Clin North Am. 1991 Feb;18(1):111-22
pubmed: 1825143
Cancer Chemother Pharmacol. 1984;12(1):13-7
pubmed: 6690068
J Am Vet Med Assoc. 2009 Aug 15;235(4):391-6
pubmed: 19681719
Vet Pathol. 2005 Mar;42(2):200-12
pubmed: 15753474
Vet Rec. 1993 Nov 27;133(22):539-42
pubmed: 8116156
Drugs Aging. 1994 Jul;5(1):59-80
pubmed: 7919640
Am Fam Physician. 2010 Jun 1;81(11):1339-46
pubmed: 20521754
BMC Vet Res. 2015 Sep 15;11:235
pubmed: 26370564
Drug Discov Today. 2016 Jul;21(7):1181-8
pubmed: 27233379
Future Oncol. 2021 May;17(13):1665-1681
pubmed: 33726508
Exp Hematol Oncol. 2018 Sep 19;7:24
pubmed: 30250760
Annu Rev Med. 2019 Jan 27;70:479-499
pubmed: 30691365
Theriogenology. 2004 May;61(7-8):1327-41
pubmed: 15036966
Anticancer Res. 2005 Mar-Apr;25(2A):839-45
pubmed: 15868917
Arch Pathol Lab Med. 2020 May;144(5):545-563
pubmed: 31928354
J Urol. 1986 Feb;135(2):303-7
pubmed: 2935644
Breast Cancer Res. 2007;9(1):R6
pubmed: 17239243